* For patients who were receiving d4T,
3TC and EFV prior to the switch, clinicians should please ensure that they have a recent undetectable viral load (VL) (~1 000 copies/ml) and normal creatinine clearance within the previous 3-6 months.
Age Sex drugs received start of ART 2-29 46 F
3TC, ZDV, EFV 33 2-44 49 F
3TC, ZDV, EFV 10 2-47 42 M
3TC, ZDV, IDV 10 2-59 36 F
3TC, ZDV, EFV, 52 IDV 2-66 36 M
3TC, ZDV, d4T, 21 ddl, EFV 2-70 30 M d4T, ddl, EFV 6 2-75 37 F
3TC, d4T, IDV 9 2-76 34 M
3TC, d4T, EFV 10 2-84 51 M
3TC, ZDV, d4T, 48 ddl, NFV 2-91 44 M
3TC, d4T, EFV, 6 IDV 2-98 32 F d4T, ddl, IDV 7 22-2 42 M
3TC, ZDV, EFV 14 22-9 33 F
3TC, ZDV, d4T, 31 ddl, EFV, IDV 22-25 30 F
3TC, ZDV, EFV, 18 IDV 22-31 42 M
3TC, d4T, IDV 8 22-33 41 F
3TC, ZDV, IDV 18 22-35 58 M
3TC, ZDV, IDV 17 22-47A 48 F
3TC, ZDV, EFV, 45 IDV 22-50 32 M
3TC, d4T, NVP 6 22-57 53 M
3TC, ZDV, EFV 7 221-75 50 F
3TC, ZDV, d4T, 29 ddl, EFV, IDV Patient no.